The watchdog's mandate allows it to block deals that would likely result in a substantial lessening of competition.
($1 = $1.0391 Canadian)
(Reporting by Alastair Sharp; Editing by Jeffrey Hodgson)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
154 CAD | -0.41% | +1.06% | +20.03% |
05:13pm | Loblaw Price Target Raised to $172 at TD | MT |
12:10pm | Loblaw Brief: Releasing 2023 ESG Report | MT |
TORONTO (Reuters) - Canada's Competition Bureau said on Monday it will review Loblaw's proposed C$12.4 billion ($11.9 billion) acquisition of Shoppers Drug Mart, and that it was difficult to say how long the review would take.
The watchdog's mandate allows it to block deals that would likely result in a substantial lessening of competition.
($1 = $1.0391 Canadian)
(Reporting by Alastair Sharp; Editing by Jeffrey Hodgson)
1st Jan change | Capi. | |
---|---|---|
+20.03% | 34.46B | |
+13.92% | 481B | |
+19.85% | 39.76B | |
+3.17% | 36.98B | |
+8.01% | 28.67B | |
+2.69% | 26.11B | |
-17.77% | 24.36B | |
+12.87% | 18.02B | |
+2.60% | 17.99B | |
+4.02% | 14.3B |